Mineralys Therapeutics MLYS
NASDAQ MLYS
$21.32 -0.26 (-1.23%)
As of: Oct 21, 2026 · 1:25 PM EDT

Mineralys Therapeutics (MLYS) Total Debt (2026)

Updated

Mineralys Therapeutics (MLYS) reported Total Debt of $97.62 million for Q2 2026.

Analysis

Mineralys Therapeutics (MLYS) Total Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,134.69 Bn 1,103.27 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 616.29 Bn 534.82 Bn 17.26 Bn 49.04 Bn
3 AbbVie 500.86 Bn 473.97 Bn 12.70 Bn 70.82 Bn
4 Merck 366.77 Bn 321.15 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 297.69 Bn 261.68 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.39 Bn 235.08 Bn 12.86 Bn 32.35 Bn
7 Amgen 235.52 Bn 190.92 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 190.49 Bn 164.69 Bn 6.22 Bn 26.25 Bn
9 Pfizer 169.46 Bn 116.11 Bn 10.94 Bn 63.19 Bn
10 Mineralys Therapeutics 1.81 Bn -751.79 Mn - 97.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.62 Mn
API Access

Mineralys Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=MLYS&period=max&api_key=YOUR_API_KEY